Loading stock data…
$1.75-0.15 (-7.89%)
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Acrivon Therapeutics, Inc. in the Healthcare sector is trading at $1.75 with a market capitalization of $85M. Wall Street consensus targets $11.50 (6 analysts), implying a +557.1% move over the next 12 months. The stock is currently 51% below its 52-week high of $3.56, remaining 2.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.67M↑ | -$19.90M↑ | -$20.12M↓ | -$19.69M↑ | -$22.65M |
| Net Income | -$17.96M↑ | -$19.04M↓ | -$18.98M↓ | -$18.23M↑ | -$21.01M |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform...